Novo Nordisk
CompanyDenmarkFounded 192369,505 staff
Novo Nordisk develops 68 assets, the furthest approved (biphasic insulin aspart in diabetes mellitus). Mostly peptide and protein or enzyme acting on GLP1R, INSR and CALCR; based in Denmark, founded in 1923.
- 68
- Assets
- Furthest stage
- Approved
- 9
- Grants
- 793
- Trials
- 759
- Signals
Pipeline
68Insulin aspart activates insulin receptors to increase glucose uptake and reduce hepatic glucose production.
Approved, Protein or enzyme, diabetes mellitus, type 2 diabetes (Phase 3)
Activates insulin receptors to increase glucose uptake and suppress hepatic glucose production.
Approved, Protein or enzyme, diabetes mellitus, type 2 diabetes (Phase 3)
Inhaled recombinant human insulin that activates the insulin receptor to reduce blood glucose
Approved, discontinued in the EU in 2008, Protein or enzyme, INSR, diabetes mellitus, type 2 diabetes
65 more assets
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
33 assets, 4 trials
1 asset, 3 trials
4 trials
In the full profile
- Evidence behind the mechanisms7
- Trials906
- Deals2
- People1
- Signals20
- Integrity notices2
- Similar companies6
Papers
Semaglutide effects showed no clear racial or ethnic differences
Clinical journal of the American Society of Nephrology : CJASN, Nov 18, 2026
Drug pair reduced weight in adults with overweight or obesity
The lancet. Diabetes & endocrinology, Nov 14, 2026
Oral semaglutide reduced total major cardiovascular events
JAMA cardiology, Nov 11, 2026
RNA slowed heart decline in mice carrying a heart disease mutation
AHA Scientific Sessions 2026 abstract, Nov 9, 2026
AHA Scientific Sessions 2026 abstract, Nov 9, 2026
Semaglutide tied to fewer kidney events in lower-risk type 2 diabetes
Research Square, Nov 5, 2026
Semaglutide lowered blood sugar across kidney disease stages
Diabetes, obesity & metabolism, Nov 4, 2026
IcoSema analysis suggests no effect on hospitalization
Metabologia, Oct 29, 2026
Presurgery exercise did not raise surgery rates in a cancer trial
JAMA network open, Oct 28, 2026
Hormone may predict blood sugar response in schizophrenia
Schizophrenia bulletin open, Oct 28, 2026
Impact of Semaglutide Introduction on the Use of Concomitant Medications: An Interrupted Time Series
Diabetes, obesity & metabolism, Oct 26, 2026
ESC Congress 2026 abstract, Oct 26, 2026
ESC Congress 2026 abstract, Oct 26, 2026
Scandinavian journal of medicine & science in sports, Oct 24, 2026
American journal of epidemiology, Oct 21, 2026
Fewer serious medical events with semaglutide in kidney trial
Kidney international, Oct 21, 2026
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Oct 16, 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Cell metabolism, Oct 8, 2026
Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)
American heart journal, Oct 7, 2026
Semaglutide may protect kidneys by reducing vascular resistance
Nature medicine, Oct 2, 2026